interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development
EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).
The EU Clinical Trials Register currently displays
44300
clinical trials with a EudraCT protocol, of which
7354
are clinical trials conducted with subjects less than 18 years old.
The register also displays information on
18700
older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see
Frequently Asked Questions ).
16 result(s) found for: Pentavalent vaccine.
Displaying page 1 of 1.
EudraCT Number: 2012-001611-23
Sponsor Protocol Number: V260-035
Start Date*: 2012-09-28
Sponsor Name:Merck Sharp & Dohme Corp., una filial de Merck & Co., Inc.
Full Title: A Double-Blind, Randomized, COntrolled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq(TM)
Medical condition: Prevention of rotavirus gastroenteritis in infants and children caused by serotypes G1, G2, G3, G4, and G serotypes that contain P1A[8] (e.g., G9)
Full Title: A Double-Blind, Randomized, Placebo-Controlled, Safety and Tolerability Study of Live Pentavalent Human-Bovine Rotavirus
Reassortant Vaccine in Chinese Healthy Adults, Children and Infants
Medical condition: Prevention of Rotavirus Gastroenteritis Caused by Serotypes G1, G2, G3, G4, and G-Serotypes Associated With P1A [8] (e.g., G9) in Infants
Disease:
Version
SOC Term
Classification Code
Term
Level
19.1
100000004862
10039232
Rotavirus gastroenteritis
LLT
Population Age: Infants and toddlers, Children, Under 18, Adults
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Full Title: Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP...
Medical condition: Prevention of Rotavirus Gastroenteritis Caused by Serotypes G1, G2, G3, G4, and G-Serotypes Associated With P1A [8] (e.g., G9) in Infants
Sponsor Name:Banyu Pharmaceutical Co., Ltd. a subsidiary of Merck & Co.,Inc, Kenilworth, New Jersey, USA
Full Title: A phase III randomized, placebo-controlled clinical trial to study the efficacy and safety of V260 in healthy infants in Japan
Medical condition: Prevention of Rotavirus Gastroenteritis Caused by Serotypes G1, G2, G3, G4, and G-Serotypes Associated With P1A [8] (e.g., G9) in Infants
Full Title: A Randomized, Double-Blinded, Tolerability and Immunogenicity
Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-
Like Particle (VLP) Vaccine (V504) Administered Concomitantly
with GARDASIL...
Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external
genital lesions, and persistent infection caused by Human Papillomavirus (HPV) 6, 11,
16, 18, 31, 33, 45, 52, an...
Full Title: A Ph III, Single Arm, Multi-Center, Open-Label Study to Assess the Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent Vaccine Quinvaxem® (DTwP-Hib-HepB Vaccine) when Administered...
Medical condition: Prophilaxis against diphtheria, tetanus, pertussis, hepatitis B and invasive Haemophilus influenzae type b disease.
Full Title: An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of the concomitant use of a live pentavalent rotavirus vaccine (RotaTeq®) and a meningococcal group C con...
Medical condition: RotaTeq® is indicated for the active immunisation of infants from age of 6 weeks for prevention of gastroenteritis due to rotavirus infection.
NeisVac-C® is indicated for active immunisation of ch...
Full Title: A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity study to assess Pentavalent Meningococcal ABCYW Vaccine formulations in Adults (18 to 25 years of age) and Adolescents (10 to 17 yea...
Medical condition: Bacterial infections and mycoses
Full Title: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Other Pediatric Vaccines in Healthy Toddlers
Medical condition: Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W)
Full Title: A Phase IIa observer-blind, randomized, controlled, age-de-escalation, single center interventional study to evaluate the safety, reactogenicity, and immune response of the GVGH iNTS vaccine agains...
Medical condition: Prevention of invasive nontyphoidal Salmonella disease
Disease:
Population Age: Infants and toddlers, Children, Under 18, Adults
Full Title: Safety and Immunogenicity of Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy Children
Medical condition: RotaTeq is an oral pentavalent vaccine indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes G1, G2, G3, G4, and G-serotypes that contain P1 (e.g...
Full Title: Safety and immunogenicity of Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis (ADACEL™) Vaccine compared to Component Pertussis Vaccine and Diphtheria and Tetanus Toxoids A...
Medical condition: Active immunization against tetanus, diphtheria and pertussis
Full Title: This Phase III multi-center study of DTaP-IPV-Hib, with or without Hep B, used as a booster vaccine in healthy infants and toddlers will be conducted with two controlled, blind-observer trial arms ...
Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus type 1, 2 and 3, prevention against invasive infections caused by Haemophilus in...
Full Title: A phase 3 open-label study to evaluate the immunogenicity and safety of a mixed (HEXA/PENTA/HEXA) primary series schedule that includes V419 (PR5I) at 2 and 6 months of age and Pediacel® at 4 month...
Medical condition: Healthy infants greater than or equal to 46 days and less than or equal to 74 days of age on the day of inclusion
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
Full Title: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF BIVALENT rLP2086 WHEN ADMINISTERED AS A 2-DOSE REGIMEN AND A FIRST-IN-HUMA...
Medical condition: Active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W and Y in individuals 10 through 25 years of age.
Disease:
Version
SOC Term
Classification Code
Term
Level
20.0
10021881 - Infections and infestations
10027249
Meningitis meningococcal
PT
Population Age: Children, Adolescents, Under 18, Adults
Subscribe to this Search
To subscribe to the RSS feed for this search click
here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options:
Number of Trials to download:
Download Content:
Download Format:
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
• EEA CTAs: Date study was authorised to proceed • Outside EU/EEA: Date study was submitted in EudraCT